Ceribell (CBLL) Q2 2026: 33% Revenue Growth Accelerates Clinical Adoption and Expands Market Reach
Ceribell delivered a robust 33% year-over-year revenue growth driven by new account additions and deeper utilization within existing accounts. The company’s strategic investments in commercial infrastructure and product innovation underpin expanding clinical adoption. Forward momentum is supported by upcoming launches of new hardware and algorithm enhancements, positioning Ceribell for accelerated growth in 2027.
Summary
- Commercial Expansion Strength: New account growth and same-store utilization gains fuel sustained revenue acceleration.
- Product Innovation Pipeline: Multiple FDA clearances and upcoming hardware platform launch enhance clinical value and market differentiation.
- Strategic Reinvestment: High gross margins enable continued investments in sales, R&D, and clinical evidence to support long-term growth.
Business Overview
Ceribell is a medical technology company that develops and commercializes point-of-care electroencephalography (EEG) systems designed for acute care settings. The company generates revenue primarily through product sales and subscription services tied to its Ceribell System, which facilitates rapid neurological monitoring. Its business segments include core seizure detection products, emerging neonate and pediatric lines, and new algorithm-based solutions such as delirium monitoring.
Performance Analysis
Ceribell reported total revenue of $28.1 million in the second quarter of 2026, marking a 33% increase year-over-year and a 6% sequential rise. Product revenue grew 33% to $21.2 million, while subscription revenue increased 30% to $6.9 million, reflecting both new account additions and deeper utilization within the existing customer base of 712 active accounts. The quarter’s revenue acceleration from 29% in Q1 to 33% in Q2 signals strengthening demand dynamics and execution.
Gross margin reached a record 92%, boosted by a $1.6 million tariff refund and manufacturing cost improvements driven by the expansion of production capabilities in Vietnam. Excluding the refund, gross margin stood at a strong 89%, underscoring effective supply chain optimization. Operating expenses rose 37% to $45.9 million, primarily due to investments in commercial infrastructure, R&D, and ongoing intellectual property litigation costs. Despite the increased operating expenses, adjusted EBITDA loss remained stable at $9.8 million, highlighting disciplined reinvestment of gross profits to fuel growth initiatives.
- Account Base Expansion: Added 32 new active accounts, continuing a consistent growth trajectory with reduced reliance on VA accounts.
- Margin Enhancement: Manufacturing diversification and tariff refunds contributed to improved gross margins, enabling reinvestment capacity.
- Operating Expense Growth: Increased sales and marketing spend, including strategic account management and clinical account manager expansion, support broader commercial efforts and upcoming product launches.
The financial results reflect a maturing commercial engine combined with ongoing product innovation, positioning Ceribell to capitalize on its large untapped market opportunity and emerging neurological monitoring segments.
Executive Commentary
"Our second quarter results reflect adoption accelerating across both new and existing accounts. Combined with the early progress of our delirium pilot and multiple new FDA 510(k) clearances, we are highly confident in the strength of our business and our mission to establish EEG as a new vital sign."
Jane Chao, Co-founder & Chief Executive Officer
"We feel confident in our ability to maintain gross margins in the high 80% range throughout 2026 based on current fair policies and believe we have built flexibility in our manufacturing capability to manage any future policy shifts."
Scott Blumberg, Chief Financial Officer
Strategic Positioning
1. Accelerating Commercial Execution Through Account Acquisition and Utilization
Ceribell’s commercial infrastructure is designed to both acquire new hospital accounts and deepen product utilization within its installed base. The company added 32 new accounts this quarter, with less dependence on VA accounts than in prior periods, reflecting a more diversified and sustainable growth model. The clinical account management team’s execution on utilization strategies, including provider engagement and department expansion, drives same-store growth, even during typical seasonal ICU census declines.
2. Expanding Clinical Value with FDA-Cleared Algorithm Enhancements
Recent FDA 510(k) clearances for artifact reduction and epileptiform abnormality detection algorithms enhance the Ceribell System’s clinical utility by improving EEG signal interpretation and expanding the detection spectrum. These algorithm upgrades, launching later this year, aim to increase neurologist adoption and utilization without additional pricing, thereby increasing platform stickiness and potentially accelerating deal velocity.
3. Next-Generation Hardware Platform to Broaden Market Reach
Ceribell is developing a new hardware platform with features such as video and ECG integration, multi-day continuous monitoring, and full montage capability via an add-on variable. This platform aims to position EEG as a new vital sign by supporting extended monitoring needs, including delirium and future indications like large vessel occlusion (LVO). The limited market release and full launch are planned for 2027, expected to open new patient populations and care settings.
4. Clinical Evidence as a Foundation for Market Leadership
The company continues to build a robust clinical evidence base, including a recent high-impact study linking clarity algorithm seizure burden to neurological outcomes. This evidence strengthens the clinical imperative for adoption and supports reimbursement efforts, including the recently secured CMS New Technology Add-On Payment (NTAP) for delirium monitoring effective October 2026.
5. Strategic Account Management and System-Level Engagement
Formation of a strategic account management team targeting regional health systems is generating a growing pipeline at the system level. Although quantitative metrics are not yet disclosed, early momentum suggests this approach could accelerate account additions and broaden Ceribell’s footprint within integrated health networks.
Key Considerations
Ceribell’s Q2 performance underscores the interplay between commercial execution, product innovation, and clinical validation in driving sustainable growth.
- Commercial Maturation: The sales force is maturing with increasing productivity over time, contributing to consistent new account additions and deeper utilization.
- Gross Margin Leverage: Manufacturing shifts and tariff refunds provide margin expansion, critical for funding R&D and sales investments.
- Emerging Product Lines: Neonate, pediatric, and delirium solutions are early-stage revenue contributors, expected to scale meaningfully in 2027.
- IP Litigation Expense: Elevated legal costs related to patent enforcement remain a notable expense but are expected to decline in the second half of 2026.
- Reimbursement Tailwind: CMS NTAP approval for delirium monitoring enhances economic incentives for adoption, supporting commercial launch plans.
Risks
Ceribell faces risks including the timing and scale of adoption for new product lines, potential shifts in manufacturing costs or tariffs, and uncertainties in intellectual property litigation outcomes. Execution risks around scaling the strategic account management function and translating clinical evidence into widespread market adoption also remain. These factors could materially impact revenue growth and profitability trajectories.
Forward Outlook
For the remainder of 2026, Ceribell raised its full-year revenue guidance to a range of $114 million to $117 million, representing 28% to 31% year-over-year growth. This reflects continued momentum in core seizure detection driven by new accounts and utilization gains. The company does not yet provide guidance for 2027 but highlighted multiple tailwinds including neonate and pediatric product scaling, delirium commercial launch, and new hardware platform introduction. Management indicated that learnings from ongoing pilots and limited releases will inform 2027 outlook updates.
Takeaways
Ceribell’s Q2 results demonstrate a well-executed growth strategy anchored in expanding clinical adoption and product innovation, supported by a strong commercial foundation and improving margins.
- Robust Growth Engine: The company’s ability to grow both its customer base and same-store utilization amid seasonal headwinds highlights operational strength and market demand.
- Innovation-Driven Differentiation: FDA-cleared algorithms and upcoming hardware enhancements build competitive barriers and expand clinical utility, positioning Ceribell as a leader in acute neurological monitoring.
- Scaling Opportunity: With less than 4% penetration in its core seizure market and emerging product lines gaining traction, Ceribell is poised for significant growth acceleration in 2027 and beyond.
Conclusion
Ceribell’s second quarter results reflect accelerating revenue growth, expanding clinical adoption, and strategic investments that strengthen its platform and market position. The company’s innovative product pipeline and reimbursement progress provide a clear path to scaling new indications and hardware offerings, setting the stage for a pivotal 2027.
Industry Read-Through
Ceribell’s progress underscores a broader industry shift toward point-of-care neurological monitoring with integrated AI-driven diagnostics. The company’s success in securing reimbursement and FDA clearances for novel algorithms highlights the growing acceptance of digital health solutions in acute care. Other players in medical technology and neurodiagnostics should watch Ceribell’s integration of hardware-software platforms and commercial strategies as a blueprint for expanding clinical utility and market penetration in specialized hospital settings.